These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 39149996)
1. Mispacking of the F87 sidechain drives aggregation-promoting conformational fluctuations in the subunit interfaces of the transthyretin tetramer. Sun X; Ferguson JA; Yang K; Stanfield RL; Dyson HJ; Wright PE Protein Sci; 2024 Sep; 33(9):e5101. PubMed ID: 39149996 [TBL] [Abstract][Full Text] [Related]
2. Mispacking of the F87 sidechain drives aggregation-promoting conformational fluctuations in the subunit interfaces of the transthyretin tetramer. Sun X; Ferguson JA; Yang K; Stanfield RL; Dyson HJ; Wright PE bioRxiv; 2024 Mar; ():. PubMed ID: 38464206 [TBL] [Abstract][Full Text] [Related]
3. Mispacking of the Phe87 Side Chain Reduces the Kinetic Stability of Human Transthyretin. Sun X; Jaeger M; Kelly JW; Dyson HJ; Wright PE Biochemistry; 2018 Dec; 57(51):6919-6922. PubMed ID: 30540442 [TBL] [Abstract][Full Text] [Related]
4. Kinetic analysis of the multistep aggregation pathway of human transthyretin. Sun X; Dyson HJ; Wright PE Proc Natl Acad Sci U S A; 2018 Jul; 115(27):E6201-E6208. PubMed ID: 29915031 [TBL] [Abstract][Full Text] [Related]
6. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953 [TBL] [Abstract][Full Text] [Related]
7. Thermodynamic Stability and Aggregation Kinetics of EF Helix and EF Loop Variants of Transthyretin. Ferguson JA; Sun X; Dyson HJ; Wright PE Biochemistry; 2021 Mar; 60(10):756-764. PubMed ID: 33645214 [TBL] [Abstract][Full Text] [Related]
8. Conformational Dynamics of an Amyloidogenic Intermediate of Transthyretin: Implications for Structural Remodeling and Amyloid Formation. Leach BI; Ferguson JA; Morgan G; Sun X; Kroon G; Oyen D; Dyson HJ; Wright PE J Mol Biol; 2024 Aug; 436(16):168673. PubMed ID: 38909653 [TBL] [Abstract][Full Text] [Related]
9. Probing the Dissociation Pathway of a Kinetically Labile Transthyretin Mutant. Sun X; Ferguson JA; Leach BI; Stanfield RL; Dyson HJ; Wright PE J Am Chem Soc; 2024 Jan; 146(1):532-542. PubMed ID: 38134439 [TBL] [Abstract][Full Text] [Related]
10. Uncovering the Mechanism of Aggregation of Human Transthyretin. Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562 [TBL] [Abstract][Full Text] [Related]
11. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320 [TBL] [Abstract][Full Text] [Related]
12. A transthyretin monomer intermediate undergoes local unfolding and transient interaction with oligomers in a kinetically concerted aggregation pathway. Sun X; Ferguson JA; Dyson HJ; Wright PE J Biol Chem; 2022 Aug; 298(8):102162. PubMed ID: 35724960 [TBL] [Abstract][Full Text] [Related]
13. Structural insight into pH-induced conformational changes within the native human transthyretin tetramer. Palaninathan SK; Mohamedmohaideen NN; Snee WC; Kelly JW; Sacchettini JC J Mol Biol; 2008 Oct; 382(5):1157-67. PubMed ID: 18662699 [TBL] [Abstract][Full Text] [Related]
14. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187 [TBL] [Abstract][Full Text] [Related]
15. Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases. Palhano FL; Leme LP; Busnardo RG; Foguel D J Biol Chem; 2009 Jan; 284(3):1443-53. PubMed ID: 18984591 [TBL] [Abstract][Full Text] [Related]
16. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis. Liang Y; Ore MO; Morin S; Wilson DJ Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799 [TBL] [Abstract][Full Text] [Related]
17. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses. Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. Green NS; Palaninathan SK; Sacchettini JC; Kelly JW J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036 [TBL] [Abstract][Full Text] [Related]
19. Exploring the Influence of Mutation on Transthyretin Aggregation in Heart Disease. Sharma A; Monu ; Biswas S Curr Comput Aided Drug Des; 2018; 14(2):125-130. PubMed ID: 29564986 [TBL] [Abstract][Full Text] [Related]
20. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]